| Dr Jared D Schneider, DC | |
|
1130 Westport Dr, Suite 5, Manhattan, KS 66502-2863 | |
| (785) 539-9113 | |
| (785) 539-9119 |
| Full Name | Dr Jared D Schneider |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 12 Years |
| Location | 1130 Westport Dr, Manhattan, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235499716 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 01-05480 (Kansas) | Primary |
| Provider Name | Jds Chiropractic Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1558761536 PECOS PAC ID: 4385864412 Enrollment ID: O20141013000639 |
News Archive
Results of the EORTC and GIMEMA AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia.
Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.
Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.
A new report based on previously unreleased data from the Department of Veterans Affairs paints a distressing portrait of an agency buried helplessly in paperwork - with a claims backlog that has gotten far worse in the past four years.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jared D Schneider, DC 301 Sw Gage Blvd, Ste 151, Topeka, KS 66606-2034 Ph: (785) 539-9113 | Dr Jared D Schneider, DC 1130 Westport Dr, Suite 5, Manhattan, KS 66502-2863 Ph: (785) 539-9113 |
News Archive
Results of the EORTC and GIMEMA AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia.
Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.
Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.
A new report based on previously unreleased data from the Department of Veterans Affairs paints a distressing portrait of an agency buried helplessly in paperwork - with a claims backlog that has gotten far worse in the past four years.
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
› Verified 6 days ago
Dr. Gary E Cleveland, DC CCEP CCSP Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 404 Humboldt St, Suite C, Manhattan, KS 66502 Phone: 785-323-1923 Fax: 785-323-1925 | |
Dr. Mark John Hatesohl, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1213 Hylton Heights Rd, Suite # 117, Manhattan, KS 66502 Phone: 785-537-8305 Fax: 785-537-2573 | |
Spinal Structural Rehabilitation Center Inc Chiropractor Medicare: Medicare Enrolled Practice Location: 445 E Poyntz Ave, Manhattan, KS 66502 Phone: 785-776-1600 Fax: 785-776-1625 | |
Manhattan Family Chiropractic, P.a. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1014 Poyntz Ave Ste C, Manhattan, KS 66502 Phone: 785-320-5151 Fax: 785-320-5159 | |
Alexis Tucker, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 711 Commons Pl, Manhattan, KS 66503 Phone: 785-320-5300 | |
Jessi Nicole Bandy, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 324c Southwind Pl, Manhattan, KS 66503 Phone: 785-320-5300 | |
Dr. Kelli Ann Nelson, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8200 South Port Dr, Manhattan, KS 66502 Phone: 785-320-6935 |